ASTX 660

Drug Profile

ASTX 660

Alternative Names: ASTX660

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma; Solid tumours

Most Recent Events

  • 20 Nov 2017 Phase-II clinical trials in Lymphoma in USA (PO) (Otsuka Pharmaceutical pipeline, November 2017)
  • 20 Nov 2017 Phase-II clinical trials in Solid tumours (Late-stage disease) in USA (PO) (Otsuka Pharmaceutical pipeline, November 2017)
  • 27 Oct 2017 Safety and pharmacokinetics data from a phase I/II clinical trial in Solid tumours and Lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top